Evidence map›Paper›PMID 20671118›Full record

Trial reportBlood2010

A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Christopher P Fox, Tracey A Haigh, Graham S Taylor, Heather M Long, Steven P Lee, Claire Shannon-Lowe, Simon O'Connor, Catherine M Bollard, Javeed Iqbal, Wing C Chan and 3 more

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00062868 phase1completednot on this map

Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma (ALCI) / Previously Known as: Administration of Neomycin Resistance Gene Marked LMP2A-Specific Cytotoxic T-Lymphocytes to Patents With Relapsed EBV-Positive Lymphoma (ALASCAR)

TypeinterventionalSponsorBaylor College of MedicineRan2003 to 2020Enrolled74ConditionsHodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, LeiomyosarcomaArmsLMP1/2 CTLs (ALCI - Group A), LMP1/2 CTLs (ALCI - Group B), LMP1/2 CTLs (ALCI - Group C), LMP2 CTLs (ALSCER - Group A), LMP2 CTLs (ALSCER - Group B)
NCT07162012 early_phase1recruitingnot on this mapstarted 2025, after this paper: background citation

The Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection for Treating Relapsed/Refractory EBV-positive Lymphoma Patients With HLA-A11:01

TypeinterventionalSponsorShanghai General Hospital, Shanghai Jiao Tong University School of MedicineRan2025 to 2029Enrolled24ConditionsNK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), DLBCLArmsEBV TCR-T
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 75 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Christopher P FoxSchool of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.
Tracey A Haigh
Graham S Taylor
Heather M Long
Steven P Lee
Claire Shannon-Lowe
Simon O'Connor
Catherine M Bollard
Javeed Iqbal
Wing C Chan
Alan B Rickinson
Andrew I Bell
Martin Rowe
University of Birmingham · GBUniversity of Nebraska Medical Center · USBaylor College of Medicine · USNottingham University Hospitals NHS Trust · GB

Funding

Tissue ResourceP50CA126752 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MALCOLM K. BRENNER, HELEN E HESLOP · 2007 to 2026
$51.4M
UT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BERRY, DONALD A · 2009 to 2011
$1.5M
Medical Research Council G0801936Medical Research Council G9901249NCI NIH HHS P50 CA126752NCI NIH HHS P50CA126752NCI NIH HHS P50 CA136411NCI NIH HHS P50CA136411-01
6 · The paper itself

Abstract

Therapeutic targeting of virus-encoded proteins using cellular immunotherapy has proved successful for Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease. However, the more limited repertoire and immunogenicity of EBV-encoded proteins in other malignancies such as Hodgkin lymphoma and extranodal natural killer (NK)/T lymphoma has been more challenging to target. The immunosubdominant latent membrane protein 2 (LMP2) is considered the optimal target in such Latency II tumors, although data relating to its expression in T/NK malignancies are limited. In addressing the validity of LMP2 as an immunotherapeutic target we found that LMP2-specific effector CD8(+) T cells recognized and killed EBV-positive NK- and T-cell tumor lines, despite an apparent absence of LMP2A protein and barely detectable levels of LMP2 transcripts from the conventional LMP2A and LMP2B promoters. We resolved this paradox by identifying in these lines a novel LMP2 mRNA, initiated from within the EBV terminal repeats and containing downstream, epitope-encoding exons. This same mRNA was also highly expressed in primary (extra-nodal) NK/T lymphoma tissue, with virtually undetectable levels of conventional LMP2A/B transcripts. Expression of this novel transcript in T/NK-cell lymphoproliferative diseases validates LMP2 as an attractive target for cellular immunotherapy and implicates this truncated LMP2 protein in NK- and T-cell lymphomagenesis. This study is registered at clinicaltrials.gov as NCT00062868.

Indexed as

Base SequenceCD8-Positive T-LymphocytesCell Line, TumorDNA PrimersEpstein-Barr Virus InfectionsGene ExpressionGenes, ViralHerpesvirus 4, HumanHumansImmunotherapy, AdoptiveKiller Cells, NaturalLeukemia, Large Granular LymphocyticLymphoma, Extranodal NK-T-CellRNA, MessengerRNA, ViralT-LymphocytesDNA PrimersEBV-associated membrane antigen, Epstein-Barr virusRNA, MessengerRNA, ViralViral Matrix Proteins

Identifiers

PMID20671118
PMCPMC2981530
OpenAlexW2016887513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.